1. Home
  2. ALXO vs UIS Comparison

ALXO vs UIS Comparison

Compare ALXO & UIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

N/A

Current Price

$1.98

Market Cap

205.9M

Sector

Health Care

ML Signal

N/A

Logo Unisys Corporation New

UIS

Unisys Corporation New

N/A

Current Price

$2.59

Market Cap

208.5M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
ALXO
UIS
Founded
2015
1942
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
205.9M
208.5M
IPO Year
2020
1994

Fundamental Metrics

Financial Performance
Metric
ALXO
UIS
Price
$1.98
$2.59
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$3.50
$5.67
AVG Volume (30 Days)
953.4K
606.6K
Earning Date
05-08-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
26.36
N/A
EPS
N/A
N/A
Revenue
N/A
$1,950,100,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$2.60
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.96
$1.97
52 Week High
$2.66
$4.98

Technical Indicators

Market Signals
Indicator
ALXO
UIS
Relative Strength Index (RSI) 49.34 36.70
Support Level $1.90 $2.58
Resistance Level $2.17 $2.65
Average True Range (ATR) 0.09 0.11
MACD -0.01 0.02
Stochastic Oscillator 37.50 2.75

Price Performance

Historical Comparison
ALXO
UIS

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

About UIS Unisys Corporation New

Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides workplace solutions featuring intelligent workplace services, proactive experience management and collaboration tools to support business growth. CA&I which provides digital transformation in the areas of cloud migration and management. ECS which provides solutions that harness secure, high-intensity enterprise computing and enable digital services through software-defined operating environments. maximum of revenue is from CA&I segment.

Share on Social Networks: